Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Cohen, Jeffrey A. (Mellen Center, Neurologic Institute, Cleveland Clinic)
Bermel, Robert (Mellen Center, Neurologic Institute, Cleveland Clinic)
Grossman, Cynthia I. (Biogen, Cambridge)
Hersh, Carrie (Cleveland Clinic (Las Vegas))
Hyland, Megan. (University of Rochester. Department of Neurology)
Mowry, Ellen M. (Johns Hopkins University. Department of Neurology)
Naismith, Robert (Washington University in St. Louis. Department of Neurology)
Naylor, Maria L. (Biogen, Cambridge)
Nicholas, Jacqueline (OhioHealth Multiple Sclerosis Center)
Rajbhandar, Rajani (Biogen, Cambridge)
Singh, Carol M. (Biogen, Cambridge)
Tintoré, Mar (Hospital Universitari Vall d'Hebron)
Zabalza, Ana (Hospital Universitari Vall d'Hebron)
Ziemssen, Tjalf (University Clinic Carl-Gustav Carus. Department of Neurology)
Williams, James R. (Biogen, Cambridge)
Montalban, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina)

Date:	2022
Abstract:	The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Three hundred twenty-two people with MS were included; 91. 9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Multiple sclerosis ; Disease-modifying therapy ; SARS-COV-2 vaccination ; Humoral immune response ; MS PATHS ; Optimal management
Published in:	Multiple sclerosis, Vol. 28 Num. 7 (january 2022) , p. 1131-1137, ISSN 1477-0970

DOI: 10.1177/13524585211061343
PMID: 34994577

7 p, 813.8 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles